Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis
IntroductionClinical trials have shown that PARP inhibitors are effective in treating patients with platinum-sensitive ovarian cancer. They have been indicated to improve progression-free survival or overall survival in patients with patients with platinum-sensitive ovarian cancer. However, there is...
Saved in:
Main Authors: | Xiaolian Peng, Jie Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-01-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1539880/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01) -
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis
by: Samuel García, et al.
Published: (2015-01-01) -
Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01) -
Regulation of stress granule maturation and dynamics by poly(ADP-ribose) interaction with PARP13
by: Shang-Jung Cheng, et al.
Published: (2025-01-01) -
Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase
by: Liset Westera, et al.
Published: (2019-01-01)